Top Trending Stocks to Consider On Monday, June 6

MIAMI, FL / ACCESSWIRE / June 6, 2016 / Daily Stock Reporter is issuing a report on four stocks to watch. Helios and Matheson Analytics Inc. (HMNY), LifeClips Inc. (LCLP), Cyclacel Pharmaceuticals, Inc. (CYCC) and Vascular Biogenics Ltd. (VBLT) have been added to our watch list today. Continue reading to find out why. - To get daily alerts on top stocks on the OTC, NASDAQ and NYSE subscribe to our newsletter at

Helios and Matheson Analytics Inc. (NASDAQ: HMNY) Is a provider of integrated Big Data technology, advanced analytics and data visualization solutions to Fortune 500 companies, and Zone Technologies, Inc., creator of RedZone Maps, a GPS-driven, real-time crime and navigation map application, announced today (6/6/16) that they plan to merge. With the new partnership, Helios and Matheson plans to leverage its artificial intelligence capabilities and deep learning and analytics expertise to enable RedZone Maps to further expand its crime mapping capabilities globally. The pending merger is subject to approval by the NASDAQ Stock Market, among other customary closing conditions. You Can View HMNY's News Here.

LifeClips Inc. (OTC: LCLP) is an innovative brand of products revolutionizing the way people capture, manage, enjoy, and share life's moments, signed a Retail Representative Agreement with Huey Long & Associates.

Mr. Long brings with him tremendous sourcing abilities, logistics expertise, marketing and sales distribution opportunities, all of which will be deployed toward Life Clips, Inc. (LCLP). Some of the channels that Mr. Long works with include, Wal-Mart, Sam's Club, AT&T, Costco, Amazon, Target, Ebags and numerous other retail stores. You Can View LCLP's News Here.

Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported today updated Phase 1 data from its DNA damage response program evaluating a combination regimen of two Cyclacel product candidates, seliciclib, a cyclin dependent kinase (CDK) inhibitor, and sapacitabine, a nucleoside analogue. The regimen was orally-administered as sequential (Part 1) or concomitant (Part 2) treatment to 67 heavily-pretreated patients with advanced solid tumors. Antitumor activity was demonstrated in a subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive for BRCA mutations (44 germline and 1 sporadic) with a 35.6% disease control rate (1 CR, 5 PR and 10 SD). Treatment durations in responders ranged between 16 and over 240 weeks. No CR or PR was observed in BRCA negative patients. Data were presented at an oral presentation at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. You Can View CYCC's News Here.

Vascular Biogenics Ltd. (NASDAQ: VBLT) is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. (VBLT) VB-111 Clinical Data Presented at ASCO Demonstrate Significant Increase in Overall Survival in Platinum-Resistant Ovarian Cancer. You Can View VBLT's News Here

ABOUT US: monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. You can subscribe to the newsletter and start receiving daily alerts. To subscribe by phone and receive messages directly to a mobile phone, text the phrase "StockAlerts" to 82257.

Legal Disclaimer

Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. A full disclaimer can be found at

EGM FIRM INC which owns, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release.

EGM FIRM INC, which owns, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice.

EGM FIRM INC which owns, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two.


Contact Email:


ReleaseID: 440803

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.